Identifying Outcome Measures for Type 2 Diabetes Value-Based Contracting Using the Delphi Method

Journal of Managed Care & Specialty Pharmacy
Lynn M NeilsonNatasha Parekh

Abstract

Value-based contracts (VBCs) between payers and pharmaceutical manufacturers link drug payments to predefined performance measures and require shared risk between both entities. It is unclear how outcome measures were selected in previously reported VBCs, and many VBCs have focused on surrogate endpoints often used in the conduct of clinical trials, which may not be valued by or of importance to patients. To identify outcome measures that are meaningful to key stakeholders and feasibly measured to inform VBCs for diabetes medications. We conducted a modified Delphi survey to incorporate views from patients (n = 9), endocrinologists (n = 5), primary care physicians (n = 4), payers (n = 3), pharmacy benefit managers (n = 3), and pharmaceutical company representatives (n = 2). A list of 12 diabetes-related outcome measures was generated from the literature and consultations with subject matter experts. Participants rated the importance of each outcome on a 5-point Likert scale and selected the 3 most meaningful outcomes. Nonpatient participants then used a Likert scale to rate the feasibility of collecting each outcome. Consensus was defined as ≥ 75% agreement on the importance and feasibility of an outcome (Likert scores 4 or 5 o...Continue Reading

References

Jun 5, 2008·JAMA : the Journal of the American Medical Association·Gunjan Y GandhiVictor M Montori
Jun 29, 2011·Diabetes Care·Patrick J O'ConnorCarol H Wysham
Oct 24, 2013·International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care·Hiske CalsbeekJozé Braspenning
Feb 6, 2014·Current Diabetes Reports·David C Aron
Mar 4, 2014·Journal of Clinical Epidemiology·Ivan R DiamondPaul W Wales
Apr 19, 2015·BMC Family Practice·Elizabeth M MagnanMaureen A Smith
Apr 6, 2016·JAMA : the Journal of the American Medical Association·Xinyang HuaPhilip Clarke
Oct 22, 2016·International Journal of Clinical Pharmacology and Therapeutics·Carlos Calvo GómezAntonio Zapatero Gaviria

❮ Previous
Next ❯

Citations

Sep 24, 2020·International Journal of Technology Assessment in Health Care·Weiwei Xu, Jing Wu
Oct 30, 2020·Journal of Managed Care & Specialty Pharmacy·Elizabeth C S SwartLynn M Neilson

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.